Tesamorelin is a synthetic analog of the complete 44-amino acid Growth Hormone Releasing Hormone (GHRH) sequence, stabilized with a trans-3-hexenoic acid modification at the N-terminus. With a molecular weight of approximately 5135.79 g/mol, it is the most complete GHRH analog in clinical and preclinical research use.
Unlike truncated GHRH fragments (e.g., sermorelin at 29 AA, CJC-1295 derivatives), tesamorelin retains the full native GHRH sequence with improved stability. Research has examined tesamorelin’s effects on GH pulse amplitude, IGF-1 levels, visceral adipose tissue, and trunk fat distribution, with a notable evidence base from HIV-associated lipodystrophy studies that produced peer-reviewed pharmacokinetic and pharmacodynamic data.
Each Etched Research vial contains 10mg of lyophilized powder, purity-verified at ≥99% via HPLC and mass spectrometry. Batch-specific Certificate of Analysis included.
Specifications:
– Molecular Formula: C221H366N72O67S
– Molecular Weight: 5135.79 g/mol
– Purity: ≥99% (HPLC + Mass Spectrometry)
– Form: Lyophilized powder
– Storage: -20°C (lyophilized); 4°C once reconstituted, use within 30 days
FOR IN VITRO RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION, INGESTION, OR ANY IN VIVO USE.
- What it is: A lab-made copy of GHRH, the growth hormone releasing hormone the brain makes.
- Researchers have studied it for: Deep belly (visceral) fat, liver fat, and related blood markers in people with HIV-associated fat changes.
- Evidence level: Human clinical trials exist, mostly in people with HIV-associated fat changes.
- The short version: Tesamorelin is one of the more heavily studied GH-axis compounds, with real human trial data behind it. Researchers measured drops in visceral and liver fat over a matter of months, almost all in people with HIV-related fat changes, not healthy adults or athletes. Those trials also logged side effects, and none of this is a safety conclusion.
Reviews
There are no reviews yet.